drugset / Trial / NCT05769660
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Timeline
- Start
- 2022-11-29
- Primary completion
- 2026-11-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVOTACICLIB | Small molecule | — | Oral |
| Background | Temozolomide | Small molecule | — | Oral |